Amesite Accelerates Growth With Launch of AI-Native NurseMagic™ EMR

Rhea-AI Summary

Amesite (NASDAQ: AMST) launched the AI-native NurseMagic EMR on Dec 19, 2025, expanding its NurseMagic platform from point-of-care to core post-acute care infrastructure.

The EMR supports coexistence with legacy systems or full replacement and the company expects to begin onboarding EMR customers in January 2026. Amesite reported strong recent growth: a 2.4x quarterly revenue increase after the May 2025 Teams+ launch, +82% revenue in Q4 after the July 2025 Enterprise tier, and a further +69% QoQ in Q1 FY2026. Website visits rose ~1,400% since January 2025. The release targets a U.S. post-acute market valued at $470B (2024) and projected to exceed $850B.

Positive

• Quarterly revenue 2.4x after May 2025 Teams+ launch
• Revenues +82% in Q4 following July 2025 Enterprise tier
• Revenue +69% QoQ in Q1 fiscal 2026
• Onboarding of NurseMagic EMR customers scheduled for January 2026
• Website visits increased ~1,400% since January 2025

Negative

• None.

Key Figures

Quarterly revenue increase 2.4x Following May 2025 launch of Teams+

Revenue growth 82% Revenue increase in Q4 after July 2025 Enterprise tier introduction

Revenue growth 69% Quarter-over-quarter revenue increase in Q1 fiscal 2026

Website traffic growth 1,400% Increase in website visits since January 2025

Generative AI value $2.6 trillion to $4.4 trillion McKinsey estimate of annual economic value from generative AI

Post-acute care market more than $470 billion U.S. post-acute care market value in 2024

Projected market size exceed $850 billion Projected U.S. post-acute care market in coming years

Product evolution period under 18 months Time from June 2024 public launch to AI-native EMR

Market Reality Check

$2.27 Last Close

Volume Volume 25,851 vs 20-day average 19,035 (relative volume 1.36x) shows elevated trading interest pre-news. normal

Technical Shares at 2.27 are trading below the 200-day MA of 2.78 and 63.81% below the 52-week high.

Peers on Argus

AMST fell 3.37% while peers were mixed: CXAI -6.8%, SMSI -5.98%, LGCL -3.96%, HTCR +3.71%, NXPL flat. No unified sector trend evident.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Oct 30	Revenue update, roadmap	Positive	-0.8%	Reported 69% QoQ revenue jump and outlined AI EMR launch plans.
Sep 11	AI product expansion	Positive	+44.4%	63% revenue growth from Enterprise and AI form-fill launch for CMS HOPE.
Jul 14	Enterprise tier launch	Positive	+1.2%	Introduced census-based Enterprise tier with EMR integration and reporting tools.
Jun 25	NurseMagic app upgrade	Positive	+0.0%	Expanded NurseMagic V3.0 to 16 languages and reported 2.4x QoQ revenue.

Pattern Detected

Recent growth- and AI-focused releases most often led to flat or positive moves, with one notable negative divergence on strong revenue growth.

Recent Company History

Over the last year, Amesite has repeatedly highlighted NurseMagic™ expansion and revenue acceleration. On Jun 25 2025, it reported a 2.4x QoQ revenue increase as NurseMagic™ V3.0 added 16 languages. On Jul 14 2025, a census-based Enterprise tier launched, followed by a 63% revenue gain and new AI form-fill tools on Sep 11 2025. By Oct 30 2025, the company cited consecutive 82% and 69% QoQ revenue growth and previewed an AI-powered EMR, which this new launch delivers.

Market Pulse Summary

The stock is up +7.0% following this news. A strong positive reaction aligns with Amesite’s pattern of meaningful moves on AI-focused NurseMagic™ milestones, such as prior AI-tagged events that averaged 13.96% moves. The launch of an AI-native EMR follows documented step-change revenue gains of 2.4x, 82%, and 69% tied to new tiers. Investors reviewing sustainability could weigh the company’s rapid expansion into post-acute infrastructure against execution risks and dependence on continued enterprise adoption.

Key Terms

emr technical

"announced the launch of the NurseMagic™ EMR, marking a significant expansion"

An electronic medical record (EMR) is a digital version of a patient’s paper chart used by a single clinic or hospital to store medical history, test results, prescriptions and treatment notes. For investors, EMR systems matter because they drive recurring software and service revenue, affect healthcare providers’ costs and efficiency, and carry regulatory, privacy and interoperability risks that can influence adoption, contract value and long‑term market growth.

post-acute care medical

"enters the infrastructure layer of post-acute care following sustained revenue expansion"

Post-acute care is the medical and support services people receive after leaving a hospital, such as rehabilitation, nursing facility stays, home health visits, and therapy programs. It matters to investors because it influences how quickly and fully patients recover, affects hospital readmission rates and ongoing treatment costs, and represents a steady revenue area in healthcare—like routine maintenance after a major repair that determines long-term performance and expense.

generative AI technical

"McKinsey estimates that generative AI could create $2.6 trillion to $4.4 trillion"

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

point-of-care medical

"extends NurseMagic™ from a point-of-care solution into core post-acute care"

"Point-of-care" refers to the location where immediate decision-making or actions happen, often involving the direct delivery of services or results. In healthcare, it describes tests or treatments performed directly at the patient's side, rather than in a distant laboratory. For investors, understanding "point-of-care" highlights the convenience, speed, and potential growth opportunities of services or products that bring solutions directly to the user or patient.

AI-generated analysis. Not financial advice.

Company enters the infrastructure layer of post-acute care following sustained revenue expansion and enterprise adoption

DETROIT, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST) today announced the launch of the NurseMagic™ EMR, marking a significant expansion of the Company’s platform following a year of strong sequential revenue growth and enterprise traction. The AI-native, modular EMR extends NurseMagic™ from a point-of-care solution into core post-acute care infrastructure, supporting both coexistence with legacy systems and full system replacement. Amesite expects to begin onboarding EMR customers in January 2026.

Amesite’s revenue growth has occurred in clear step changes aligned with the rollout of progressively higher-value product tiers, progressing from Individual to Teams, Teams+, and Enterprise offerings. Following the May 2025 launch of Teams+, the Company reported a 2.4x increase in quarterly revenue. With the July 2025 introduction of its Enterprise tier, priced on patient census rather than individual users, revenues increased 82% in the fourth quarter. Continued expansion of Enterprise capabilities and industry outreach drove an additional 69% quarter-over-quarter revenue increase in the first quarter of fiscal 2026.

McKinsey estimates that generative AI could create $2.6 trillion to $4.4 trillion in annual economic value, primarily when AI is embedded into core operating systems rather than used as standalone tools.¹ In under 18 months since its June 2024 public launch, NurseMagic™ has progressed from an AI assistant for individual clinicians to an enterprise platform with census-based pricing and now an AI-native EMR.

The U.S. post-acute care market is one of healthcare’s largest and fastest-growing segments, valued at more than $470 billion in 2024 and projected to exceed $850 billion in the coming years. Growth is driven by an aging population, rising chronic disease burden, and sustained payer and policy shifts toward lower-cost, home-based care models.² Technology-enabled post-acute care has demonstrated meaningful cost savings and clinical outcomes.³ NurseMagic™ currently serves post-acute providers across home health, hospice, skilled nursing, senior living, and home care.

“What makes this launch particularly powerful from a sales perspective is the flexibility it gives our customers, and how it strengthens our position in the market,” said Brandon Owens, VP of Sales at Amesite. “We can work alongside existing EMRs, delivering immediate operational and financial impact without disruption, or we can replace them entirely with a full AI‑native EMR built for how post‑acute care operates today. That optionality changes the dynamic in every conversation. Buyers don’t have to choose between incremental improvement and wholesale change. In competitive situations, that’s a very strong position to sell from, and one that legacy systems simply can’t match.”

“Since January 2025, website visits have increased by nearly 1,400%, reflecting growing awareness of deployable AI solutions in post-acute care,” said Madison Bush, Director of Corporate Operations at Amesite. “As we expanded NurseMagic™’s capabilities and enterprise offerings, that interest translated into higher engagement across our digital channels, supporting continued momentum leading into the launch of the NurseMagic™ EMR.”

“Reaching this stage reflects the disciplined way we have built NurseMagic™,” said Dr. Ann Marie Sastry, CEO and Founder of Amesite. “With an AI-native EMR, demonstrated enterprise adoption, and a pricing model aligned with patient volumes, we are extending our platform into the core systems that post-acute care organizations depend on. The launch of the NurseMagic™ EMR marks an important step in our strategy to deliver durable, infrastructure-level solutions anchored in customer requirements.”

About Amesite Inc.

Amesite (NASDAQ: AMST) is an AI-driven software company focused on delivering technology platform solutions. Its flagship product, NurseMagic™, is designed to streamline clinical documentation, support point-of-care decision-making, and deliver actionable operational insight, and has expanded from an assistant for individual clinicians into an enterprise platform that includes an electronic medical record (EMR) offering. NurseMagic™ is used by used by over 100 professions across all 50 states and over 20 countries. Built on proprietary AI and designed to meet applicable regulatory and security requirements, the platform serves B2B and B2C users with capabilities that include workflow integration and multilingual support.

Forward-Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations

ir@amesite.com

Sources

1. https://www.mckinsey.com/capabilities/tech-and-ai/our-insights/the-economic-potential-of-generative-ai-the-next-productivity-frontier
2. https://www.gminsights.com/industry-analysis/u-s-post-acute-care-market
3. https://www.ama-assn.org/public-health/population-health/hospital-home-saves-lives-and-money-cms-report
   
   

FAQ

What is Amesite announcing with the NurseMagic EMR on Dec 19, 2025 (AMST)?

Amesite announced the launch of an AI-native NurseMagic EMR that can coexist with legacy systems or fully replace them, with customer onboarding starting January 2026.

How did Amesite's revenue change after product tier launches in 2025 (AMST)?

After the May 2025 Teams+ launch revenue rose 2.4x; after the July 2025 Enterprise tier revenues were +82% in Q4, then +69% QoQ in Q1 FY2026.

What does the NurseMagic EMR mean for AMST shareholders and commercialization timing?

The EMR extends NurseMagic into core infrastructure and the company expects to begin onboarding customers in January 2026, potentially accelerating enterprise sales momentum.

Which post-acute care segments does NurseMagic serve and what market size does Amesite cite?

NurseMagic serves home health, hospice, skilled nursing, senior living, and home care; Amesite cites a U.S. post-acute market of $470B (2024) projected to exceed $850B.

Will NurseMagic EMR replace existing EMRs or integrate with them (AMST)?

Amesite says the NurseMagic EMR supports both coexistence with legacy EMRs and full system replacement, offering customers deployment flexibility.

What recent digital engagement metrics did Amesite report ahead of the EMR launch (AMST)?

The company reported website visits increased by about 1,400% since January 2025, reflecting rising interest in deployable AI for post-acute care.